Iceland’s Kvika Bank reported Q2 2026 profit before tax of ISK 1,545 million, down 23.7% year on year. Post-tax profit fell 37.2% to ISK 903 million. Net interest income rose 1.7% to ISK 3,013 million and the net interest margin was unchanged at 4.0%. Net fee and commission income slid 26.8% to ISK 1,416 million, weighing on results.

Martin Marietta has priced a $5.5 billion offering of senior notes across five maturities. The deal includes $750 million of 4.850% notes due 2029, $1,250 million of 5.200% notes due 2032, $1,000 million of 5.400% notes due 2034, $1,500 million of 5.625% notes due 2036, and $1,000 million of 6.375% notes due 2056. The 2029 notes will be issued at 99.936% of par.

Computer Modelling Group reported fiscal 2026 first-quarter revenue of $27.8 million, down 6% year over year. Recurring revenue fell 3% to $20.3 million, while adjusted EBITDA declined 10% to $6.4 million. Earnings per share were $0.02, down 50%, and free cash flow slipped 22% to $3.5 million. The board also approved a quarterly cash dividend of $0.01 per share.

Computer Modelling Group Ltd. said its board has approved a substantial issuer bid to repurchase for cancellation up to C$20,000,000 of its common shares. The company plans to buy back shares at a 7% to 20% premium. Over the 12month period ended August 11, 2026, the stock’s closing prices ranged from a low of C$3.44 to a high of C$6.54.

Westport released its financial results for the second quarter of 2026, highlighting sharp growth at Cespira, its joint venture with Volvo Group, on strong demand for LNG HPDI fuel systems. Cespira’s revenue rose 125% year over year and gross profit improved 298%, while Westport’s total revenue fell to $2.7 million from $12.5 million a year earlier. The company also said it completed a private placement in June for initial gross proceeds of about US$10 million, with the potential for another US$10 million over the next two years through warrant exercises.

Oculis has signed an asset purchase agreement with Accure Therapeutics to acquire the worldwide development and commercial rights to Privosegtor and, in a separate closing, ACT02. The consideration includes a $3.8 million upfront cash payment and up to 2,050,000 Oculis ordinary shares, with lockup and milestone-based vesting terms. Privosegtor is an investigational neuroophthalmology drug candidate that has not received regulatory approval for commercial use in any country, while ACT02 is an early-stage preclinical neurology candidate. Oculis said the deal is intended to strengthen its pipeline and strategic position in neuroophthalmology.

Zelluna ASA said shareholder Inven2 AS received 446,752 new shares through the company’s share issue, lifting its ownership from 4.9% to 6.3%. The increase triggers a mandatory large-shareholding disclosure under Section 42 of the Norwegian Securities Trading Act. The company said the filing is a statutory disclosure and does not involve changes in control, business strategy or financial data, and has no direct impact on the fundamentals of ONUS shares.

CBL International received a Nasdaq notice on August 12, 2025 after its shares closed below $1 for 30 consecutive trading days, triggering a 180-day compliance window through February 9, 2026. The company carried out a 1-for-13 share consolidation on July 20, 2026, after which its Class B ordinary shares closed at $1 or higher for 10 straight sessions from July 20 to July 31. On that basis, Nasdaq confirmed the company has regained compliance with the minimum bid price requirement. The development reflects a listing compliance update rather than a change in fundamentals or a direct driver of asset prices.

Asymchem Group (stock codes: 002821.SZ / 6821.HK) and investors including Hillhouse Qirui injected a total of RMB 1.2397 billion (approximately US$184 million) into its biologics CDMO unit AsymBio, with Asymchem contributing RMB 1.05 billion. Following the capital increase, Asymchem Group’s shareholding in AsymBio will rise to 83.4965%. The move strengthens the group’s capital base and strategic positioning in biologics outsourcing manufacturing, directly benefiting its A-share and Hong Kong-listed entities.